A structural adhesive is a little bit different than a regular adhesive in that it’s an adhesive that can achieve 1,000 ...

The Boston-based biotech is having a ball after signing a deal with Novartis to the tune of $150 million for a molecular glue degrader, developed using the company’s QuEEN platform, that makes ...

The molecular glue degrader medicines furthest along in development are potential cancer treatments, but Monte Rosa Therapeutics is also researching how this therapeutic modality can treat ...

Novartis will apply Monte Rosa Therapeutics’ target discovery platform to develop its T and B cell-modulating molecular glue degraders targeting the VAV1 protein—starting with its Phase I ...